medigraphic.com
ISSN 1561-3194 (Electronic)

2016, Number 2

<< Back Next >>

Rev Ciencias Médicas 2016; 20 (2)

Overall survival of epithelial ovarian cancer in Pinar del Rio as prognostic factors

Labrador AM, Sánchez AY, Quintero PW, Benitez FY, Gener RY

Language: Spanish
References: 15
Page: 212-219
PDF size: 289.45 Kb.


ABSTRACT

Introduction: Ovarian cancer is the fourth cause of cancer deaths in the western population and also constitutes the gynecological pathology with the greatest lethality.
Objective: To evaluate the influence of evolutionary prognostic factors of epithelial ovarian cancer on overall survival in patients of Provincial Cancer Center, III Congress Hospital of Pinar del Rio, during the period 2010-2014.
Method: Analytical, prospective, longitudinal study; in a sample of 62 patients. In the statistical analysis the variables considered as prognostic factors (taken from the medical records file Provincial Cancer Center) were correlated with overall survival by Log Rank method; overall survival was estimated through the Kaplan Meier method. Survival plots were made so that the visual information generated could provide a clearer idea of the results of the investigation.
Results: The overall survival was 72.6%. Factors that influenced it were: clinical stage, residual tumor size and sensitivity to platinum salts (p ‹ 0.05). The histologic variety had no influence on the evolution of the patients (p › 0.05).
Conclusions: Prognostic factors of overall survival of epithelial ovarian cancer in Pinar del Rio are: clinical stage, residual tumor size and sensitivity to platinum salts.


REFERENCES

  1. Rojas S, Bravo E, Alonso C, Parry S. Videotoracoscopía en cáncer de ovario avanzado con sospecha de compromiso torácico. RevChilObstetGinecol [Internet]. 2012 [citado 9 Mar 2014]; 77(3): [aprox. 4 p.]. Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-75262012000300004&lang=pt

  2. Acosta Peñaloza JA. Carcinoma epitelial de ovario. Hacia los equipos multidisciplinarios. Rev Coloma Cancerol [Internet]. 2013 [citado 4 Feb 2015]; 17(4): [aprox. 5 p.]. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0123 -90152013000400001&lang=pt

  3. Cortés-Funes, Hernán; Colomer Bosch, Ramón. Tratado de Oncología. Tomo I. 2009. pp 999-1040.

  4. Villegas Valverde CA, Arango Prado del MC. Participación de los linfocitos T reguladores en el cáncer de ovario. Rev Cubana ObstetGinecol [Internet]. 2013 Mar [citado 4 Feb 2015]; 39(1): [aprox. 8 p.]. Disponible en: http://scieloprueba.sld.cu/scielo.php?script=sci_arttext&pid=S0138 -600X2013000100004&lng=es&nrm=iso

  5. NCCN Guidelines Version 1.2015. Epithelian Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer. 2015

  6. Serum levels of macrophage migration-inhibitory factor (MIF) have diagnostic, predictive and prognostic roles in epithelial ovarian cancer patients.Tumor Markers, Tumor Targeting and Translational Cancer Research 2013 35:1438. [citado 26 Jun 2015]. Disponible en: http://health.springer.com/article/10.1007/s13277-013-1438-z/fulltext.html

  7. Cress RD, Chen YS, Morris CR, Petersen M, Leiserowitz GS. Characteristics of Long-Term Survivors of Epithelial Ovarian Cancer. Obstet Gynecol. 2015 Sep;126(3):491-7. [consultado 11 de septiembre 2015]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/26244529

  8. Nowak-Markwitz E , Spaczyński M. Ovarian cancer—modern approach to its origin and histogenesis. Ginekol Pol. 2012 Jun;83(6):454-7. [consultado 11 de septiembre 2015]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22880466

  9. Lozneanu L, Avadanei R, Cîmpean AM, Giuşcă SE, Amălinei C, Căruntu ID. Relationship between the proangiogenic role of EG-VEGF, clinicopathological characteristics and survival in tumoral ovary. Rev Med Chir Soc Med NatI asi. 2015 Apr-Jun;119(2):461-5. [consultado 11 de septiembre 2015]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/26204653

  10. Hu L, Cong L. Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer. Oncol Rep. 2015 Aug 20. doi: 10.3892/or.2015.4212. [consultado 11 de septiembre 2015]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/26323668

  11. Solmaz U, Mat E, Dereli ML, Turan V, Peker N, Tosun G et al. Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone? 2015 May-Jun;20(3):847-54. [consultado 11 de septiembre 2015]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/26214639

  12. Yulan Ren, Rong Jiang, Sheng Yin, Chao You, Dongli Liu, Xi Cheng et al. Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational study. BMC Cancer. 2015; 15: 583. Published online [en línea] 2015 Aug;13. [consultado 11 de septiembre 2015]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535562/

  13. Grabowskil JP , Mardas M , Markowska A , Markowska J . Evaluation of residual tumor locations in advanced ovarian cancer patients after incomplete primary cytoreduction. Eur J GynaecolOncol. 2015;36(3):274-7. [consultado 11 de septiembre 2015]

  14. Smits A, Lopes A, Das N, Kumar A, Cliby W, Smits E. Surgical morbidity and clinical outcomes in ovarian cancer - the role of obesity. BJOG. 2015 Sep 2. doi: 10.1111/1471-0528.13585. [consultado 11 de septiembre 2015]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/26331299

  15. McEvoy LM, O'Toole SA, Spillane CD, Martin CM, Gallagher MF, Stordal B et al. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer. BMC Cancer. 2015 Jul 25;15:547. [consultado 11 de septiembre 2015] http://www.ncbi.nlm.nih.gov/pubmed/26205780




2020     |     www.medigraphic.com